vs
是德科技（KEYS）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
是德科技的季度营收约是Revvity的1.8倍（$1.4B vs $772.1M），是德科技净利率更高（16.4% vs 12.7%，领先3.7%），是德科技同比增速更快（10.3% vs 5.9%），是德科技自由现金流更多（$187.0M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 6.2%）
是德科技是一家美国企业，主营电子测试测量设备与软件的研发、生产业务。公司由安捷伦科技拆分而来，核心产品线继承自惠普测试测量部门上世纪60年代末至千禧年间开发的相关产品，后独立为现有品牌。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
KEYS vs RVTY — 直观对比
营收规模更大
KEYS
是对方的1.8倍
$772.1M
营收增速更快
KEYS
高出4.4%
5.9%
净利率更高
KEYS
高出3.7%
12.7%
自由现金流更多
KEYS
多$25.2M
$161.8M
两年增速更快
RVTY
近两年复合增速
6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $772.1M |
| 净利润 | $233.0M | $98.4M |
| 毛利率 | 61.2% | — |
| 营业利润率 | 15.3% | 14.5% |
| 净利率 | 16.4% | 12.7% |
| 营收同比 | 10.3% | 5.9% |
| 净利润同比 | 419.2% | 3.9% |
| 每股收益（稀释后） | $1.35 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KEYSRVTY
| Q4 25 | $1.4B | $772.1M | ||
| Q3 25 | $1.4B | $698.9M | ||
| Q2 25 | $1.3B | $720.3M | ||
| Q1 25 | $1.3B | $664.8M | ||
| Q4 24 | $1.3B | $729.4M | ||
| Q3 24 | $1.2B | $684.0M | ||
| Q2 24 | $1.2B | $691.7M | ||
| Q1 24 | $1.3B | $649.9M |
净利润KEYSRVTY
| Q4 25 | $233.0M | $98.4M | ||
| Q3 25 | $191.0M | $46.7M | ||
| Q2 25 | $257.0M | $53.9M | ||
| Q1 25 | $169.0M | $42.2M | ||
| Q4 24 | $-73.0M | $94.6M | ||
| Q3 24 | $389.0M | $94.4M | ||
| Q2 24 | $126.0M | $55.4M | ||
| Q1 24 | $172.0M | $26.0M |
毛利率KEYSRVTY
| Q4 25 | 61.2% | — | ||
| Q3 25 | 61.7% | 53.6% | ||
| Q2 25 | 62.3% | 54.5% | ||
| Q1 25 | 63.2% | 56.5% | ||
| Q4 24 | 62.3% | — | ||
| Q3 24 | 62.0% | 56.3% | ||
| Q2 24 | 62.7% | 55.7% | ||
| Q1 24 | 64.6% | 54.6% |
营业利润率KEYSRVTY
| Q4 25 | 15.3% | 14.5% | ||
| Q3 25 | 17.3% | 11.7% | ||
| Q2 25 | 15.8% | 12.6% | ||
| Q1 25 | 16.8% | 10.9% | ||
| Q4 24 | 17.9% | 16.3% | ||
| Q3 24 | 16.8% | 14.3% | ||
| Q2 24 | 14.6% | 12.4% | ||
| Q1 24 | 17.6% | 6.8% |
净利率KEYSRVTY
| Q4 25 | 16.4% | 12.7% | ||
| Q3 25 | 14.1% | 6.7% | ||
| Q2 25 | 19.7% | 7.5% | ||
| Q1 25 | 13.0% | 6.4% | ||
| Q4 24 | -5.7% | 13.0% | ||
| Q3 24 | 32.0% | 13.8% | ||
| Q2 24 | 10.4% | 8.0% | ||
| Q1 24 | 13.7% | 4.0% |
每股收益（稀释后）KEYSRVTY
| Q4 25 | $1.35 | $0.86 | ||
| Q3 25 | $1.10 | $0.40 | ||
| Q2 25 | $1.49 | $0.46 | ||
| Q1 25 | $0.97 | $0.35 | ||
| Q4 24 | $-0.41 | $0.77 | ||
| Q3 24 | $2.22 | $0.77 | ||
| Q2 24 | $0.72 | $0.45 | ||
| Q1 24 | $0.98 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.9B | $919.9M |
| 总债务越低越好 | $2.5B | — |
| 股东权益账面价值 | $5.9B | $7.3B |
| 总资产 | $11.3B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.43× | — |
8季度趋势，按日历期对齐
现金及短期投资KEYSRVTY
| Q4 25 | $1.9B | $919.9M | ||
| Q3 25 | $2.6B | $931.4M | ||
| Q2 25 | $3.1B | $991.8M | ||
| Q1 25 | $2.1B | $1.1B | ||
| Q4 24 | $1.8B | $1.2B | ||
| Q3 24 | $1.6B | $1.2B | ||
| Q2 24 | $1.7B | $2.0B | ||
| Q1 24 | $1.7B | $1.7B |
总债务KEYSRVTY
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $1.8B | — | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.8B | — | ||
| Q2 24 | $1.8B | — | ||
| Q1 24 | $1.8B | — |
股东权益KEYSRVTY
| Q4 25 | $5.9B | $7.3B | ||
| Q3 25 | $5.7B | $7.4B | ||
| Q2 25 | $5.5B | $7.6B | ||
| Q1 25 | $5.2B | $7.6B | ||
| Q4 24 | $5.1B | $7.7B | ||
| Q3 24 | $5.2B | $7.9B | ||
| Q2 24 | $4.9B | $7.9B | ||
| Q1 24 | $4.8B | $7.8B |
总资产KEYSRVTY
| Q4 25 | $11.3B | $12.2B | ||
| Q3 25 | $10.7B | $12.1B | ||
| Q2 25 | $10.5B | $12.4B | ||
| Q1 25 | $9.4B | $12.4B | ||
| Q4 24 | $9.3B | $12.4B | ||
| Q3 24 | $9.3B | $12.8B | ||
| Q2 24 | $9.0B | $13.4B | ||
| Q1 24 | $9.1B | $13.4B |
负债/权益比KEYSRVTY
| Q4 25 | 0.43× | — | ||
| Q3 25 | 0.45× | — | ||
| Q2 25 | 0.46× | — | ||
| Q1 25 | 0.35× | — | ||
| Q4 24 | 0.35× | — | ||
| Q3 24 | 0.34× | — | ||
| Q2 24 | 0.37× | — | ||
| Q1 24 | 0.38× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $225.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $187.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 13.2% | 21.0% |
| 资本支出强度资本支出/营收 | 2.7% | 2.6% |
| 现金转化率经营现金流/净利润 | 0.97× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $1.3B | $509.4M |
8季度趋势，按日历期对齐
经营现金流KEYSRVTY
| Q4 25 | $225.0M | $182.0M | ||
| Q3 25 | $322.0M | $138.5M | ||
| Q2 25 | $484.0M | $134.3M | ||
| Q1 25 | $378.0M | $128.2M | ||
| Q4 24 | $359.0M | $174.2M | ||
| Q3 24 | $255.0M | $147.9M | ||
| Q2 24 | $110.0M | $158.6M | ||
| Q1 24 | $328.0M | $147.6M |
自由现金流KEYSRVTY
| Q4 25 | $187.0M | $161.8M | ||
| Q3 25 | $291.0M | $120.0M | ||
| Q2 25 | $457.0M | $115.5M | ||
| Q1 25 | $346.0M | $112.2M | ||
| Q4 24 | $321.0M | $149.8M | ||
| Q3 24 | $222.0M | $125.6M | ||
| Q2 24 | $74.0M | $136.6M | ||
| Q1 24 | $281.0M | $129.7M |
自由现金流率KEYSRVTY
| Q4 25 | 13.2% | 21.0% | ||
| Q3 25 | 21.5% | 17.2% | ||
| Q2 25 | 35.0% | 16.0% | ||
| Q1 25 | 26.7% | 16.9% | ||
| Q4 24 | 24.9% | 20.5% | ||
| Q3 24 | 18.2% | 18.4% | ||
| Q2 24 | 6.1% | 19.7% | ||
| Q1 24 | 22.3% | 20.0% |
资本支出强度KEYSRVTY
| Q4 25 | 2.7% | 2.6% | ||
| Q3 25 | 2.3% | 2.6% | ||
| Q2 25 | 2.1% | 2.6% | ||
| Q1 25 | 2.5% | 2.4% | ||
| Q4 24 | 3.0% | 3.4% | ||
| Q3 24 | 2.7% | 3.3% | ||
| Q2 24 | 3.0% | 3.2% | ||
| Q1 24 | 3.7% | 2.7% |
现金转化率KEYSRVTY
| Q4 25 | 0.97× | 1.85× | ||
| Q3 25 | 1.69× | 2.97× | ||
| Q2 25 | 1.88× | 2.49× | ||
| Q1 25 | 2.24× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 0.66× | 1.57× | ||
| Q2 24 | 0.87× | 2.87× | ||
| Q1 24 | 1.91× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KEYS
| Transferred At Point In Time | $790.0M | 56% |
| Electronicindustrial | $429.0M | 30% |
| Transferred Over Time | $200.0M | 14% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
